SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria Ambaglio, Martin Jädersten, Monika Jansson, Chiara Elena, Anna Gallì, Gunilla Walldin, Matteo G Della Porta, Klas Raaschou-Jensen, Erica Travaglino, Klaus Kallenbach, Daniela Pietra, Viktor Ljungström, Simona Conte, Emanuela Boveri, Rosangela Invernizzi, Richard Rosenquist, Peter J. CampbellMario Cazzola, Eva Hellström Lindberg

Research output: Contribution to journalArticle

Abstract

Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) characterized by isolated erythroid dysplasia and 15% or more bone marrow ring sideroblasts. Ring sideroblasts are found also in other MDS subtypes, such as refractory cytopenia withmultilineage dysplasia and ring sideroblasts (RCMD-RS). Ahigh prevalence of somaticmutations of SF3B1was reportedin these conditions.Toidentifymutation patterns that affect disease phenotype and clinical outcome, we performed a comprehensive mutation analysis in 293 patients with myeloid neoplasm and 1% or more ring sideroblasts. SF3B1 mutations were detected in 129 of 159 cases (81%) of RARS or RCMD-RS. Among other patients with ring sideroblasts, lower prevalence ofSF3B1mutations andhigher prevalence of mutations in other splicing factor genes were observed (P <.001). In multivariable analyses, patients with SF3B1 mutations showed significantly better overall survival (hazard ratio [HR], .37; P 5 .003) and lower cumulative incidence of disease progression (HR50.31; P5.018) comparedwith SF3B1-unmutated cases. The independent prognostic value of SF3B1 mutation was retained in MDS without excess blasts, as well as in sideroblastic categories (RARS and RCMD-RS). Among SF3B1-mutated patients, coexisting mutations in DNA methylation geneswere associated with multilineage dysplasia (P5.015) but had no effect on clinical outcome. TP53 mutationswere frequently detected in patients without SF3B1 mutation, and were associated with poor outcome. Thus, SF3B1 mutation identifies a distinct MDS subtype that is unlikely to develop detrimental subclonal mutations and is characterized by indolent clinical course and favorable outcome.

Original languageEnglish
Pages (from-to)233-241
Number of pages9
JournalBlood
Volume126
Issue number2
DOIs
Publication statusPublished - Jul 9 2015

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint Dive into the research topics of 'SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts'. Together they form a unique fingerprint.

  • Cite this

    Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jädersten, M., Jansson, M., Elena, C., Gallì, A., Walldin, G., Porta, M. G. D., Raaschou-Jensen, K., Travaglino, E., Kallenbach, K., Pietra, D., Ljungström, V., Conte, S., Boveri, E., Invernizzi, R., Rosenquist, R., ... Lindberg, E. H. (2015). SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood, 126(2), 233-241. https://doi.org/10.1182/blood-2015-03-633537